PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma - Journal of Molecular Medicine
Source : https://link.springer.com/article/10.1007/s00109-023-02313-8
Abstract Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma with highly heterogeneous clinical courses. Paired-box 5 (PAX5), the regulator of B cell differentiation and growth, is abnormally expressed...
Conclusions/Relevance: This study provides insight into the potential role of PAX5 in MCL, and the novel risk scoring system MIPI-SP optimizes the risk stratification and facilitates prognosis evaluation in MCL patients.
-
Leukemia and Lymphoma Connect2yrKey Points • Source: Journal of Molecular Medicine • Conclusions/Relevance: “This study provides insight into the potential role of PAX5 in MCL, and the novel risk scoring system MIPI-SP optimizes the risk stratification and Show More
Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36741209/
Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma in the US. For nearly 2 decades, standard front-line treatment has consisted of chemoimmunotherapy with rituximab,...
Conclusions/Relevance: This article provides a practical approach to managing a newly diagnosed patient with DLBCL.
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37145975/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: This open-label, fixed-sequence, phase 1 study was conducted to determine the effect of CYP3A induction by rifabutin on zanubrutinib PK when co-administered in healthy male volunteers. The results of this study in conjunction with safety and efficacy data from other clinical studies can be used to support the appropriate dose...
Comprehensive FISH testing using FFPE tissue microarray of primary lymph node tissue identifies secondary cytogenetic abnormalities in Mantle Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37094546/
FISH using FFPE primary lymph node tissue can detect secondary cytogenetic abnormalities in patients with MCL which are associated with an inferior prognosis. An expanded FISH panel including MYC, CDKN2A,...
Conclusion: FISH using FFPE primary lymph node tissue can detect secondary cytogenetic abnormalities in patients with MCL which are associated with an inferior prognosis. An expanded FISH panel including MYC, CDKN2A, TP53 and ATM should be considered in cases where anomalous IHC expression or is seen for these markers or if the patient...
FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37088993/
FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma
Relevance: Adult patients with relapsed or refractory follicular lymphoma now have access to a new treatment option. Mosunetuzumab-axgb was granted accelerated approval by the US Food and Drug Administration on December 22, 2022.1 Mosunetuzumab is a bispecific antibody that represents a new class of fixed-duration cancer immunotherapy.